Roblan / Shutterstock.com
25 November 2015Americas
Kyle Bass targets Alpex speckled tablet patent
Hedge fund manager Kyle Bass has requested that the Patent and Trial and Appeal Board (PTAB) review the validity of a patent owned by Alpex Pharma.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
2 December 2015 Hedge fund manager Kyle Bass has filed another inter partes review, teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.
Editor's picks
Editor's picks
Big Pharma
2 December 2015 Hedge fund manager Kyle Bass has filed another inter partes review, teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.
Big Pharma
2 December 2015 Hedge fund manager Kyle Bass has filed another inter partes review, teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.